Tuesday, January 27, 2004 :: Imaging Diagnostic Systems Is Awarded Its Fifteenth U.S. Patent
PRESS RELEASE: Imaging Diagnostic Systems Is Awarded Its Fifteenth U.S. Patent


FORT LAUDERDALE, Fla., Jan. 28 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS) announced today that the U.S. Patent application filed March 14, 2002, titled: “METHOD FOR IMPROVING THE ACCURACY OF DATA OBTAINED IN A LASER IMAGING APPARATUS,” was awarded by the United States Patent and Trademark Office and assigned to Imaging Diagnostic Systems as U.S. Patent No. 6,681,130.

The theory of this invention was to provide a method for improving the accuracy of data obtained in a diagnostic medical imaging apparatus that employs a near-infrared laser and array of detectors with variable gain amplifiers that can accommodate the wide dynamic range of signals available from the detectors.
Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLM® system is the first patented breast-imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography. The CTLM® system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
www.imds.com
Media Relations:
Margie Adelman
madelman@adelmancommunications.com
561.347.6768

SOURCE Imaging Diagnostic Systems, Inc.
/CONTACT: Margie Adelman, +1-561-347-6768, or
madelman@adelmancommunications.com, for Imaging Diagnostic Systems /
/Web site: http://www.imds.com/
(IMDS)

Monday, January 26, 2004 :: Imaging Diagnostic Systems Is Awarded Its Fourteenth U.S. Patent
PRESS RELEASE: Imaging Diagnostic Systems Is Awarded Its Fourteenth U.S. Patent

FORT LAUDERDALE, Fla., Jan. 27 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS) announced today that the U.S. Patent application submitted June 12, 1998 titled: “PHANTOM FOR OPTICAL AND MAGNETIC RESONANCE IMAGING QUALITY CONTROL,” was awarded by the United States Patent and Trademark Office and assigned to Imaging Diagnostic Systems as U.S. Patent No. 6,675,035.
This invention relates to phantoms for use in optical and magnetic resonance imaging that emulates the optical characteristics of breast tissue, that resembles the breast in shape and size, as an integral component of a quality assurance protocol to verify the performance of the medical imaging apparatus being evaluated.
Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLM® system is the first patented breast-imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography. The CTLM® system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations:
www.imds.com
Media Relations:
Margie Adelman
madelman@adelmancommunications.com
561.347.6768

SOURCE Imaging Diagnostic Systems, Inc.
/CONTACT: Margie Adelman, +1-561-347-6768, or
madelman@adelmancommunications.com, for Imaging Diagnostic Systems /
/Web site: http://www.imds.com /
(IMDS)

Sunday, January 25, 2004 :: IMAGING DIAGNOSTIC SYSTEMS EXHIBITS AT THE 28th INTERNATIONAL HOSPITAL, MEDICAL EQUIPMENT & SERVICES CONFERENCE IN DUBAI, UNITED ARAB EMIRATES
IMAGING DIAGNOSTIC SYSTEMS EXHIBITS AT THE 28th INTERNATIONAL HOSPITAL, MEDICAL EQUIPMENT & SERVICES CONFERENCE IN DUBAI, UNITED ARAB EMIRATES

FOR IMMEDIATE RELEASE
Fort Lauderdale, Florida, January 26, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) exhibited its CTLMâ system at the 28th Arab Health conference in Dubai, United Arab Emirates, January 18-21, 2004, increasing their exposure in the international markets. The Arab Health conference leads the way in healthcare exhibitions and conferences in the Middle East. It targets UAE, Saudi Arabia, Kuwait, Bahrain, Oman and Qatar, as well as Lebanon, Jordan, Syria and CIS countries.
Arab Health has been established as the leading healthcare exhibition in the Middle East attracting professionals such as senior decision-makers, ministry officials, hospital managers, directors of hospitals and labs, suppliers, officers, and the leading healthcare dealers and distributors from across the region. Over 950 companies from across the globe showcased their latest in medical technology and over 16,000 medical professionals attended in the previous year.

“ This year the conference attendance was at an all-time high and the response for the CTLMâ system was overwhelming. I am pretty confident that it will prove to be a very beneficial and profitable show for Imaging Diagnostic Systems,” stated Jean Medici/International Sales Director for Imaging Diagnostic Systems.

Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.

Investor Relations: Media Relations:
www.imds.com Margie Adelman
madelman@adelmancommunications.com
561.347.6768

Wednesday, December 31, 1969 :: Imaging Diagnostic Systems Installs CTLM® in Tianjin, China
Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System

Imaging Diagnostic Systems Installs CTLM® in Tianjin, China

Fort Lauderdale, Florida, September 5, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast cancer imaging systems, has installed a CT Laser Mammography (CTLM®) system at the Tianjin Medical University’s Cancer Institute and Hospital, the largest breast disease center in China.

Research at the Cancer Institute will be led by Professor Bao Runxian, Director of Radiology. Data will be collected under three research protocols designed to improve current methods of addressing breast cancer imaging and treatment follow-up. Professor E. Milne, MD, IMDS Director of Clinical Research will train the University doctors on CTLM adjunctive image interpretation and protocol methodologies.

The Tianjin system is the second research system installed in China. The first, at Beijing’s Friendship Hospital, enabled CTLM clinical procedures to become listed on the Regional schedule for patient payments. IMDS plans to install several more research CTLM systems in China to accelerate market adoption of the new laser breast imaging technique.

Both the incidence and the number of deaths from breast cancer has tripled in Chinese women, making it the second most common cause of death from cancer for Chinese women. Early detection may provide women with better treatment options. Sources in China report that the incidence of breast cancer in has increased by at least 27% over the past decade and 40% of the Chinese women diagnosed with breast cancer die within five years because the cancer is already very advanced when it is diagnosed.

The Cancer Institute and Hospital is planning the 4th Congress of the World Society for Breast Health, in Tianjin, October 18th through October 21st. The Congress is sponsored by the World Society for Breast Health, the China Oncology Society and the Chinese Medical Association. IDSI Beijing will present CTLM clinical findings at the meeting.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com

Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com